↓ Skip to main content

Dove Medical Press

Article Metrics

Nomegestrol acetate-17b-estradiol for oral contraception

Overview of attention for article published in Patient preference and adherence, June 2013
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (76th percentile)
  • Good Attention Score compared to outputs of the same age and source (79th percentile)

Mentioned by

twitter
3 tweeters
wikipedia
2 Wikipedia pages

Citations

dimensions_citation
6 Dimensions

Readers on

mendeley
22 Mendeley
Title
Nomegestrol acetate-17b-estradiol for oral contraception
Published in
Patient preference and adherence, June 2013
DOI 10.2147/ppa.s39371
Pubmed ID
Authors

Anne Burke

Abstract

Oral contraceptives remain a popular method of contraception over 50 years after their introduction. While safe and effective for many women, the failure rate of oral contraception is about 8%. Concerns about the risk of venous thromboembolism continue to drive the search for the safest oral contraceptive formulations. The oral contraceptive NOMAC-E2 contains nomegestrol acetate (NOMAC) 2.5 mg + 17b-estradiol (E2) 1.5 mg. The approved dosing regimen is 24 days of active hormone, followed by a 4-day hormone-free interval. NOMAC is a progestin derived from testosterone, which has high bioavailability, rapid absorption, and a long half-life. Estradiol, though it has a lower bioavailability, has been successfully combined with NOMAC in a monophasic oral contraceptive. Two recently published randomized controlled trials demonstrate that NOMAC-E2 is an effective contraceptive, with a Pearl Index less than one pregnancy per 100 woman-years. The bleeding pattern on NOMAC-E2 is characterized by fewer bleeding/spotting days, shorter withdrawal bleeds, and a higher incidence of amenorrhea than the comparator oral contraceptive containing drospirenone and ethinyl estradiol. The adverse event profile appears to be acceptable. Few severe adverse events were reported in the randomized controlled trials. The most common adverse events were irregular bleeding, acne, and weight gain. Preliminary studies suggest that NOMAC-E2 does not seem to have negative effects on hemostatic and metabolic parameters. While no one oral contraceptive formulation is likely to be the optimum choice for all women, NOMAC-E2 is a formulation with effectiveness comparable with that of other oral contraceptives, and a reassuring safety profile.

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 22 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Argentina 1 5%
Unknown 21 95%

Demographic breakdown

Readers by professional status Count As %
Student > Master 6 27%
Student > Ph. D. Student 4 18%
Researcher 3 14%
Student > Bachelor 2 9%
Student > Postgraduate 2 9%
Other 5 23%
Readers by discipline Count As %
Medicine and Dentistry 10 45%
Biochemistry, Genetics and Molecular Biology 3 14%
Agricultural and Biological Sciences 2 9%
Unspecified 2 9%
Pharmacology, Toxicology and Pharmaceutical Science 2 9%
Other 3 14%

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 September 2016.
All research outputs
#3,112,166
of 12,522,829 outputs
Outputs from Patient preference and adherence
#232
of 1,052 outputs
Outputs of similar age
#35,891
of 152,764 outputs
Outputs of similar age from Patient preference and adherence
#9
of 43 outputs
Altmetric has tracked 12,522,829 research outputs across all sources so far. This one has received more attention than most of these and is in the 74th percentile.
So far Altmetric has tracked 1,052 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.5. This one has done well, scoring higher than 77% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 152,764 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 76% of its contemporaries.
We're also able to compare this research output to 43 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 79% of its contemporaries.